Join
Live feed
·
PRReleasevia Quantisnow
NeuBase Therapeutics Inc. logo

NeuBase Therapeutics Presents New Preclinical Data at MDA 2022 for Its Myotonic Dystrophy Type 1 Program Demonstrating Splice Rescue, Nuclear Aggregate Resolution, and Myotonia Reversal

ByQuantisnow·Wall Street's wire, on your screen.
NBSE· NeuBase Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NBSE (NeuBase Therapeutics Inc.) and more on Quantisnow.